Vaisala published preliminary net sales figures for Q1/24, missing our estimates with roughly 15% y/...
We expect that cost increases will happen at a slower pace than revenue growth in 2024.
XVIVO presented the overall results from the European Heart study, based on 203 patients across 15 c...
Zoomability Int AB (”Zoomability” eller ”Bolaget”) meddelade den 10 april att det tidigare kommunice...
Skapar ett konkurrenskraftigt bolag i regionen Samgåendet mellan Aros och Besqab skapar en av de led...
Redeye leaves a comment following Alzinova’s announcement of updated in-depth analysis of data from ...
Redeye lowers its forecasts for Q1 while leaving the rest of 2024 roughly unchanged.
Q1 report due 24 April Q1e net sales SEK 554m, EBITA SEK 78m Trading at 8x NTM EV/EBITA vs 10y avg.
AVTECH published key figures which fell short by 5% and 7% below RRe for net sales and EBITDA, respe...
Redeye notes that Neonode's CEO is leaving the company effective immediately, and therefore provides...
Scandinavian Astor Group (”Astor Group” eller ”bolaget”) meddelade den 9 april att bolaget har ingåt...
Redeye endorses today’s news that the nomination committee has proposed Jan Lundberg, Eli Lilly's an...
Redeye comments on yesterday’s news from Sozap, where the company announced a rights issue of SEK11.
Redeye leaves an initial comment following the Q2 report published by Newbury this morning.
Redeye comments on the outcome in the rights issue, with a subscription rate of 71%.
- Embla (name change from Ossur) reports Q1 on 23 April in morning - Solid start to 2024 with 5% Q1e...
Despite the recent acquisition of Bishopsgate, we lower adjusted EBIT by 2-3% for 2024E-26E ahead of...
Order intake likely to improve Sports & outdoor demand should normalise during '24 '24e-'26e EBIT up...
Redeye leaves a comment following Faron’s announcement of a change in its CEO position.
While IRLAB Therapeutics’ immediate focus is on advancing mesdopetam in levodopa-induced dyskinesia ...
